Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$9.57 - $35.08 $69,861 - $256,084
7,300 Added 45.34%
23,400 $336 Million
Q2 2024

Aug 06, 2024

BUY
$12.35 - $26.11 $198,835 - $420,371
16,100 New
16,100 $58.8 Million
Q2 2023

Aug 11, 2023

BUY
$21.59 - $27.88 $373,507 - $482,324
17,300 New
17,300 $13.5 Million
Q4 2022

Jan 17, 2023

BUY
$27.82 - $44.16 $1.39 Million - $2.21 Million
50,100 New
50,100 $26.2 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $172M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Gallacher Capital Management LLC Portfolio

Follow Gallacher Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gallacher Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gallacher Capital Management LLC with notifications on news.